• All
  • Advocacy Hub
  • Advocacy Update
  • Blog Posts
  • GHC Announcements
  • News Center
  • Statement
142nd WHO Executive Board Session Briefing

Organized by

142nd WHO Executive Board Session Briefing
January 17
1:30 PM – 2:30 PM EST



(Deadline for submission is January 16)

Join GHC for a webinar briefing to gather insights regarding the 142nd WHO Executive Board (EB) session, which opens in Geneva on January 22. The webinar will feature remarks from GHC members and partners and will address critical EB discussions on WHO’s leadership priorities, including the draft thirteenth general programme of work 2019–2023, TB, and NCDs. U.S. government staff have been invited to attend the briefing. Remarks will be followed by a Q&A/Discussion with participants. GHC is now accepting questions from participants ahead of the webinar for the Q&A session. Please complete this form by no later than January 16.

Special guests include:

1) Garret Grigsby, Director of the Office of Global Affairs, U.S. Department of Health & Human Services

2) Jenifer Healy, Chief of Staff, Office of Global Affairs, U.S. Department of Health & Human Services


World Hepatitis Summit 2017

Organized by
World Health Organization (WHO) and World Hepatitis Alliance (WHA)

November 1 – 3
São Paulo, Brazil

The World Hepatitis Summit is a large-scale, global biennial event to advance the viral hepatitis agenda. It is a joint initiative between the World Health Organization (WHO) and the World Hepatitis Alliance (WHA). Brazil has been chosen to partner and host the World Hepatitis Summit 2017, in recognition of the country’s ongoing national initiatives and consistent international leadership in the area of viral hepatitis.

The theme of this year’s Summit is Implementing the Global Health Sector Strategy on Viral Hepatitis (GHSS): Towards the elimination of hepatitis as a public health threat. This programme seeks to promote advocacy, encourage the exchange of ideas and facilitate learning to use in the fight against viral hepatitis. It has been created by a Programme Secretariat and sub-Committees made up of experts in the field of hepatitis and civil society groups. Additional content and speakers will continue to be added over the next few months.

Webinar on HIV Drug Resistance (HIVDR)

Organized by

July 28
9.30 AM – 11.00 AM EDT

Briefing on new WHO reports profiled at the 9th IAS Conference in Paris
2017 HIVDR Report 2017
WHO Guidelines on the public health response to pretreatment HIVDR
Global Action Plan on HIVDR, 2017-2021
View these reports

Webinar Details:

To help our planning, please email sunderlandd@who.int to indicate if you plan to come.

Join Web-Ex Meeting:
Access Code: 842 806 065

Join from a video system or application:
Dial 842806065@who-meeting.webex.com.

Join by phone:
UK Toll: +44-203-478-5289
USA/Canada Toll: +1 631-267-4890

More global call-in numbers


Recognizing the need for a coordinated global effort to prevent HIVDR from undermining the attainment of global targets and to provide the most effective treatment to people living with HIV, WHO has developed the 2017 HIVDR ReportWHO Guidelines on the public health response to pretreatment HIVDR, and Global Action Plan on HIVDR, 2017-2021.

Silvia Bertagnolio leads WHO’s work on HIVDR and will make a presentation on the reports.  She will be joined by Anton Ofield-Kerr, Director of Equal International, which supported the development of the Global Action Plan.  The webinar will provide an opportunity to discuss HIVDR and consider feedback from the IAS conference, as well as consider inputs from Global Health Council members.

The HIV drug resistance report 2017 presents recent HIVDR data from a nationally representative survey of pretreatment and acquired HIVDR. Results are contextualized by systematic reviews of the published literature assessing HIVDR in adults and children. The report informs prevention activities and the public health response to HIVDR.

The Guidelines on the public health response to pretreatment HIV drug resistance answer the following questions:

1.  At what prevalence of HIVDR amongst people starting ART should a public health intervention be triggered?

2.  What is the appropriate response(s) in countries with elevated levels of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance?

The Global Action Plan on HIVDR, 2017-2021, developed in collaboration with partners and stakeholders, provides a five-year framework for action centered on five strategic objectives.  The framework outlines key actions for all partners involved in the global response to HIVDR, and links to indicators to track implementation of the plan.

A Conversation with Phillipe Douste-Blazy on His Candidacy for Director-General of WHO

A Conversation with Phillipe Douste-Blazy on His Candidacy for Director-General of WHO

Thursday, September 29, 2016
2:30 – 4:00 pm

Center for Strategic & International Studies
2nd Floor A
1616 Rhode Island Ave, NW
Washington, D.C.


On Thursday, September 29, 2016, the CSIS Global Health Policy Center will host a conversation with Phillipe Douste-Blazy, Under-Secreatary-General of the United Nations and Special Advisor to the Secreatary-General on Innovative Financing for Development, on his candidacy for Director General of the World Health Organization.

J. Stephen Morrison, Senior Vice President and Director, CSIS Global Health Policy Center, will moderate.


Show more